Evidence map›Paper›PMID 38924560›Full record

ArticleXenotransplantation

Non-Classical Swine Leukocyte Antigens SLA-6, -7, and -8, Are Xenoantigens for Some Waitlisted Patients.

Luz Reyes, Zheng-Yu Wang, Jose Estrada, Christopher Burlak, Victor Novara Gennuso, Sam Ho, Matt Tector, Alfred Joseph Tector

Abstract read
In one paragraph

Article in Xenotransplantation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Lung rehabilitation using xenogeneic cross-circulation does not lead to hyperacute rejection in a human lung transplantation model.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2025
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Luz ReyesDepartment of Surgery, University of Miami School of Medicine, Miami, Florida, USA.
Zheng-Yu WangDepartment of Surgery, University of Miami School of Medicine, Miami, Florida, USA.
Jose EstradaDepartment of Surgery, University of Miami School of Medicine, Miami, Florida, USA.
Christopher BurlakDepartment of Surgery, University of Miami School of Medicine, Miami, Florida, USA.ORCID 0000-0002-3460-406X
Victor Novara GennusoDepartment of Surgery, University of Miami School of Medicine, Miami, Florida, USA.
Sam HoGift of Hope Organ and Tissue Donor Network, Itasca, Illinois, USA.
Matt TectorMakana Therapeutics, Miami, Florida, USA.ORCID 0009-0004-0994-9180
Alfred Joseph TectorDepartment of Surgery, University of Miami School of Medicine, Miami, Florida, USA.ORCID 0000-0002-9865-8382

Funding

Tumor Biology Research ProgramP30CA240139 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI George S. Grills · 2019 to 2026
$24.1M
Tissue and organ specific human B cell immunity: Supplement - Metabolic Risk Factors and Inflammation in PASC DevelopmentU19AI142737 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LUND, FRANCES E. · 2019 to 2023
$19.7M
Strategies to Optimize Pig-to-Primate Kidney Xenograft SurvivalU01AI126322 · NIAID · UNIVERSITY OF MINNESOTA · PI Andrew B Adams, A Joseph Tector · 2021 to 2026
$8.9M
National Cancer Institute of the National Institutes of Health P30CA240139National Institute of Allergy and Infectious DiseasesNCI NIH HHS P30 CA240139NIAID NIH HHS U01 AI126322NIAID NIH HHS U19 AI142737NIH HHS 5U19AI142737
6 · The paper itself

Abstract

Attack of donor tissues by pre-formed anti-pig antibodies is well known to cause graft failure in xenotransplantation. Genetic engineering of porcine donors to eliminate targets of these pre-formed antibodies coupled with advances in immunosuppressive medicines have now made it possible to achieve extended survival in the pre-clinical pig-to-non-human primate model. Despite these improvements, antibodies remain a risk over the lifetime of the transplant, and many patients continue to have pre-formed donor-specific antibodies even to highly engineered pigs. While therapeutics exist that can help mitigate the detrimental effects of antibodies, they act broadly potentially dampening beneficial immunity. Identifying additional xenoantigens may enable more targeted approaches, such as gene editing, to overcome these challenges by further eliminating antibody targets on donor tissue. Because we have found that classical class I swine leukocyte antigens are targets of human antibodies, we now examine whether related pig proteins may also be targeted by human antibodies. We show here that non-classical class I swine leukocyte proteins (SLA-6, -7, -8) can be expressed at the surface of mammalian cells and act as antibody targets.

Indexed as

Antigens, HeterophileHistocompatibility Antigens Class ITransplantation, HeterologousAnimalsAnimals, Genetically ModifiedGraft RejectionHistocompatibility Antigens Class IIHumansSwineAntigens, HeterophileHistocompatibility Antigens Class IHistocompatibility Antigens Class IIswine leukocyte antigenMHCnon‐classicalSLA

Identifiers

PMID38924560
PMCPMC11927765

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.